English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessStocksGlenmark Pharma share price falls 2.02% in early trade

    Glenmark Pharma share price falls 2.02% in early trade

    With the stock currently trading at Rs 2,091.00, Glenmark Pharma's performance reflects a dynamic interplay of market sentiment and corporate actions.

    Alpha Desk
    August 01, 2025 / 09:35 IST
    Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer
     
     
    live
    • bselive
    • nselive
    Volume
    Todays L/H
    More

    Shares of Glenmark Pharma declined by 2.02% to Rs 2,091.00 in early trade on Friday. At 09:28 am, the stock experienced a price fall compared to its previous close.

    Financial Snapshot:

    The following tables provide a summary of Glenmark Pharma's key financial data:

    Income Statement - Quarterly (Consolidated):

    Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024
    SalesRs 3,256 CroreRs 3,387 CroreRs 3,433 CroreRs 3,244 CroreRs 3,062 Crore
    Other IncomeRs 11 CroreRs 31 CroreRs 39 CroreRs 31 CroreRs 773 Crore
    Total IncomeRs 3,267 CroreRs 3,418 CroreRs 3,473 CroreRs 3,275 CroreRs 3,836 Crore
    Total ExpenditureRs 3,193 CroreRs 2,910 CroreRs 2,952 CroreRs 2,773 CroreRs 3,156 Crore
    EBITRs 74 CroreRs 508 CroreRs 521 CroreRs 501 CroreRs 703 Crore
    InterestRs 66 CroreRs 52 CroreRs 48 CroreRs 39 CroreRs 148 Crore
    TaxRs 3 CroreRs 108 CroreRs 118 CroreRs 122 CroreRs 1,769 Crore
    Net ProfitRs 4 CroreRs 348 CroreRs 354 CroreRs 340 CroreRs -1,214 Crore

    The revenue for the quarter ending March 2025 was Rs 3,256 Crore, compared to Rs 3,062 Crore for the quarter ending March 2024.

    Income Statement - Yearly (Consolidated):

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    SalesRs 13,321 CroreRs 11,813 CroreRs 12,990 CroreRs 12,304 CroreRs 10,943 Crore
    Other IncomeRs 113 CroreRs 839 CroreRs 316 CroreRs 166 CroreRs 50 Crore
    Total IncomeRs 13,435 CroreRs 12,653 CroreRs 13,306 CroreRs 12,471 CroreRs 10,994 Crore
    Total ExpenditureRs 11,829 CroreRs 12,100 CroreRs 12,088 CroreRs 10,732 CroreRs 9,258 Crore
    EBITRs 1,606 CroreRs 552 CroreRs 1,218 CroreRs 1,739 CroreRs 1,735 Crore
    InterestRs 207 CroreRs 515 CroreRs 349 CroreRs 298 CroreRs 353 Crore
    TaxRs 352 CroreRs 1,867 CroreRs 491 CroreRs 447 CroreRs 412 Crore
    Net ProfitRs 1,047 CroreRs -1,830 CroreRs 377 CroreRs 993 CroreRs 970 Crore

    The annual sales for March 2025 was Rs 13,321 Crore, an increase compared to Rs 11,813 Crore in March 2024.

    Cash Flow (Consolidated):

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Operating ActivitiesRs -827 CroreRs -265 CroreRs 625 CroreRs 1,108 CroreRs 1,131 Crore
    Investing ActivitiesRs 2 CroreRs 4,560 CroreRs -528 CroreRs -333 CroreRs -675 Crore
    Financing ActivitiesRs 787 CroreRs -3,906 CroreRs -77 CroreRs -520 CroreRs -441 Crore
    OthersRs 55 CroreRs -174 CroreRs 13 CroreRs 17 CroreRs 13 Crore
    Net Cash FlowRs 17 CroreRs 215 CroreRs 32 CroreRs 272 CroreRs 27 Crore
    Balance Sheet (Consolidated):
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Share CapitalRs 28 CroreRs 28 CroreRs 28 CroreRs 28 CroreRs 28 Crore
    Reserves & SurplusRs 8,821 CroreRs 7,801 CroreRs 9,445 CroreRs 9,058 CroreRs 7,036 Crore
    Current LiabilitiesRs 5,967 CroreRs 5,818 CroreRs 5,045 CroreRs 4,689 CroreRs 4,201 Crore
    Other LiabilitiesRs 1,233 CroreRs 710 CroreRs 4,852 CroreRs 3,307 CroreRs 4,337 Crore
    Total LiabilitiesRs 16,049 CroreRs 14,358 CroreRs 19,371 CroreRs 17,083 CroreRs 15,603 Crore
    Fixed AssetsRs 5,251 CroreRs 4,804 CroreRs 7,380 CroreRs 6,837 CroreRs 6,452 Crore
    Current AssetsRs 9,295 CroreRs 7,428 CroreRs 9,873 CroreRs 8,282 CroreRs 7,359 Crore
    Other AssetsRs 1,502 CroreRs 2,125 CroreRs 2,117 CroreRs 1,963 CroreRs 1,791 Crore
    Total AssetsRs 16,049 CroreRs 14,358 CroreRs 19,371 CroreRs 17,083 CroreRs 15,603 Crore
    Contingent LiabilitiesRs 0 CroreRs 1,193 CroreRs 477 CroreRs 559 CroreRs 544 Crore
    Key Financial Ratios:
    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Basic EPS (Rs.)37.11-53.2210.5333.3734.38
    Diluted Eps (Rs.)37.11-53.2210.5333.3734.38
    Book Value [Excl. Reval Reserve]/Share (Rs.)313.60278.09348.70334.48250.36
    Dividend/Share (Rs.)2.502.502.502.502.50
    Face Value11111
    Gross Profit Margin (%)18.5017.2219.9720.2119.50
    Operating Margin (%)14.8512.3015.2716.2515.45
    Net Profit Margin (%)7.86-12.132.908.078.86
    Return on Networth / Equity (%)11.83-19.133.1310.3613.73
    ROCE (%)19.6217.0113.8416.1314.83
    Return On Assets (%)6.52-10.451.535.516.21
    Current Ratio (X)1.561.281.961.771.75
    Quick Ratio (X)1.050.841.371.231.21
    Debt to Equity (x)0.250.130.460.400.66
    Interest Coverage Ratios (X)11.903.947.428.346.05
    Asset Turnover Ratio (%)0.880.700.710.420.43
    Inventory Turnover Ratio (X)1.081.151.311.851.85
    3 Yr CAGR Sales (%)4.053.9010.4911.689.82
    3 Yr CAGR Net Profit (%)2.6637.38-30.263.649.85
    P/E (x)41.53-18.0144.1313.2513.52
    P/B (x)4.913.441.381.371.86
    EV/EBITDA (x)17.8312.956.316.077.80
    P/S (x)3.262.291.011.011.20
    Corporate Actions:

    Glenmark Pharma has a history of corporate actions, including dividends and stock splits. Recent announcements include:

    • Newspaper Advertisement for transfer of Equity Shares to IEPF Authority on July 25, 2025.
    • Credit rating rationale issued by India Ratings and Research on July 23, 2025.
    • Audio recording of Investor Day 2025 held on July 16, 2025.

    The company has announced final dividends regularly. The most recent was on May 24, 2024, for Rs 2.50 per share.

    Glenmark Pharma had a 1:1 bonus issue on March 4, 2005.

    The company had stock splits on September 10, 2007 (2 to 1) and October 23, 2003 (10 to 2).

    Moneycontrol analysis indicates very bullish sentiment as of August 1, 2025.

    Alpha Desk
    first published: Aug 1, 2025 09:34 am

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347